Dysbiosis of the Gut Microbiome in Lung Cancer

Study information

Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/23

study design

case-control

Citation

PMID PubMed identifier for scientific articles.

31065547

DOI Digital object identifier for electronic documents.

10.3389/fcimb.2019.00112

URI

Authors

Zhuang H, Cheng L, Wang Y, Zhang YK, Zhao MF, Liang GD, Zhang MC, Li YG, Zhao JB, Gao YN, Zhou YJ, Liu SL

Journal

Frontiers in cellular and infection microbiology

Year

2019

Keywords:

16S rRNA, biomarkers, gut microbiota, lung cancer, microbial diversity, next generation sequencing

Lung cancer (LC) is one of the most serious malignant tumors, which has the fastest growing morbidity and mortality worldwide. A role of the lung microbiota in LC pathogenesis has been analyzed, but a comparable role of the gut microbiota has not yet been investigated. In this study, the gut microbiota of 30 LC patients and 30 healthy controls were examined via next-generation sequencing of 16S rRNA and analyzed for diversity and biomarkers. We found that there was no decrease in significant microbial diversity (alpha diversity) in LC patients compared to controls (P observed = 0.1422), while the composition (beta diversity) differed significantly between patients and controls (phylum [stress = 0.153], class [stress = 0.16], order [stress = 0.146], family [stress = 0.153]). Controls had a higher abundance of the bacterial phylum Actinobacteria and genus Bifidobacterium, while patients with LC showed elevated levels of Enterococcus. These bacteria were found as possible biomarkers for LC. A decline of normal function of the gut microbiome in LC patients was also observed. These results provide the basic guidance for a systematic, multilayered assessment of the role of the gut microbiome in LC, which has a promising potential for early prevention and targeted intervention.

Experiment 1

Edit History Delete

Flag for review

Your review change was submittedDuplicate this Experiment Add a new Signature

Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/23

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): Claregrieve1, WikiWorks

Subjects

Location of subjects: China

Host species Species from which microbiome was sampled. Contact us to have more species added.: Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Lung cancer alveolar cell carcinoma,cancer of lung,lung cancer,lung cancer, protection against,lung neoplasm,malignant lung neoplasm,malignant lung tumor,malignant neoplasm of lung,malignant neoplasm of the lung,malignant tumor of lung,malignant tumor of the lung,Nonsmall cell lung cancer,Lung cancer

Group 0 name Corresponds to the control (unexposed) group for case-control studies: controls

Group 1 name Corresponds to the case (exposed) group for case-control studies: lung cancer

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: lung cancer patients

Group 0 sample size Number of subjects in the control (unexposed) group: 30

Group 1 sample size Number of subjects in the case (exposed) group: 30

Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any): 3 months

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: V3-V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Illumina

Statistical Analysis

Statistical test: LEfSe

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.05

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: Yes

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness: unchanged

Richness Number of species: unchanged

Signature 1

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/23

Curated date: 2021/01/10

Curator: Rimsha Azhar

Revision editor(s): Claregrieve1, WikiWorks

Source: Figure 3, Supplementary Figure S3

Description: Differential microbial abundance between lung cancer patients and healthy controls by LefSe

Abundance in Group 1: increased abundance in lung cancer

NCBI	Quality Control	Links
Actinomyces
Actinomycetaceae
Actinomycetales
Atopobium
Enterococcaceae
Enterococcus
Thomasclavelia
Holdemanella
Intestinimonas
Macrococcus
Raoultella
Staphylococcaceae

Revision editor(s): Claregrieve1, WikiWorks

Signature 2

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by Claregrieve1 on 2022/12/23

Curated date: 2021/01/10

Curator: Rimsha Azhar

Revision editor(s): Claregrieve1, WikiWorks

Source: Figure 3, Supplementary Figure S3

Description: Differential microbial abundance between lung cancer patients and healthy controls by LefSe

Abundance in Group 1: decreased abundance in lung cancer

NCBI	Quality Control	Links
Actinomycetes
Adlercreutzia
Alteromonadaceae
Alteromonadales
Alteromonas
Bifidobacteriaceae
Bifidobacteriales
Bifidobacterium
Clostridiaceae
Collinsella
Coprobacter
Coriobacteriaceae
Coriobacteriales
Dorea
Lachnospira
Lentibacillus
Moryella
Peptoniphilus
Peptostreptococcus
Pseudobutyrivibrio
Ruminiclostridium
Sutterella

Revision editor(s): Claregrieve1, WikiWorks